These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38710206)

  • 61. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial.
    Huang ML; Luo BY; Hu JB; Wang SS; Zhou WH; Wei N; Hu SH; Xu Y
    Aust N Z J Psychiatry; 2012 Mar; 46(3):257-64. PubMed ID: 22391283
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study.
    Kanchanatawan B; Tangwongchai S; Sughondhabhirom A; Suppapitiporn S; Hemrunrojn S; Carvalho AF; Maes M
    Neurotox Res; 2018 Apr; 33(3):621-633. PubMed ID: 29327213
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder.
    Iovieno N; Shelton RC; Petrie SR; Cusin C; Fava M; Papakostas GI
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 28749091
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
    Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA
    J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
    Bakish D; Bose A; Gommoll C; Chen C; Nunez R; Greenberg WM; Liebowitz M; Khan A
    J Psychiatry Neurosci; 2014 Jan; 39(1):40-9. PubMed ID: 24144196
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: a randomized placebo-controlled study.
    Altamura AC; Dell'Osso B; Buoli M; Bosi M; Mundo E
    Int Clin Psychopharmacol; 2008 Jul; 23(4):198-202. PubMed ID: 18545057
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
    Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
    J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.
    DeMartinis NA; Yeung PP; Entsuah R; Manley AL
    J Clin Psychiatry; 2007 May; 68(5):677-88. PubMed ID: 17503976
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans.
    Wong ML; Dong C; Flores DL; Ehrhart-Bornstein M; Bornstein S; Arcos-Burgos M; Licinio J
    Am J Psychiatry; 2014 Dec; 171(12):1297-309. PubMed ID: 25220861
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Roohi-Azizi M; Arabzadeh S; Amidfar M; Salimi S; Zarindast MR; Talaei A; Akhondzadeh S
    Clin Neuropharmacol; 2017; 40(1):1-5. PubMed ID: 28085707
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
    Sheffrin M; Driscoll HC; Lenze EJ; Mulsant BH; Pollock BG; Miller MD; Butters MA; Dew MA; Reynolds CF
    J Clin Psychiatry; 2009 Feb; 70(2):208-13. PubMed ID: 19210951
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.
    Durgam S; Earley W; Guo H; Li D; Németh G; Laszlovszky I; Fava M; Montgomery SA
    J Clin Psychiatry; 2016 Mar; 77(3):371-8. PubMed ID: 27046309
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression.
    Serra-Millàs M; López-Vílchez I; Navarro V; Galán AM; Escolar G; Penadés R; Catalán R; Fañanás L; Arias B; Gastó C
    Psychopharmacology (Berl); 2011 Jul; 216(1):1-8. PubMed ID: 21308467
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical response augments NK cell activity independent of treatment modality: a randomized double-blind placebo controlled antidepressant trial.
    Frank MG; Hendricks SE; Burke WJ; Johnson DR
    Psychol Med; 2004 Apr; 34(3):491-8. PubMed ID: 15259834
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
    Yu YM; Gao KR; Yu H; Shen YF; Li HF
    J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.